What is B. Riley's Estimate for Vaxart FY2027 Earnings?

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - B. Riley issued their FY2027 EPS estimates for Vaxart in a note issued to investors on Monday, November 18th. B. Riley analyst M. Mamtani anticipates that the biotechnology company will post earnings of $0.09 per share for the year. The consensus estimate for Vaxart's current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart's FY2028 earnings at $0.13 EPS.

Separately, Oppenheimer assumed coverage on shares of Vaxart in a report on Thursday, August 15th. They set an "outperform" rating and a $4.00 target price for the company.

Vaxart Trading Down 2.0 %

VXRT traded down $0.01 during midday trading on Wednesday, hitting $0.61. 821,744 shares of the company were exchanged, compared to its average volume of 2,488,843. The company's 50 day simple moving average is $0.79 and its 200 day simple moving average is $0.77. The firm has a market capitalization of $107.84 million, a price-to-earnings ratio of -1.58 and a beta of 0.70. Vaxart has a 1-year low of $0.52 and a 1-year high of $1.54.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. RA Capital Management L.P. purchased a new stake in shares of Vaxart during the first quarter worth about $20,000,000. Vanguard Group Inc. increased its stake in Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company's stock worth $10,984,000 after buying an additional 1,404,391 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company's stock valued at $2,660,000 after acquiring an additional 2,095,274 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock worth $2,160,000 after acquiring an additional 346,725 shares during the last quarter. Finally, Monaco Asset Management SAM purchased a new stake in shares of Vaxart during the second quarter worth approximately $402,000. 18.05% of the stock is owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.